



ALS Research Forum e-Newsletter Vol. 209

December 5, 2018

Visit the [ALS Research Forum](#) to read the complete stories featured in this e-newsletter. Friends and colleagues can sign up for the newsletter [here](#). Follow us on [Facebook](#) and [Twitter](#) for the latest updates.

Conference News

[Beyond the Nucleus: TDP-43 Sticks Together, For Better or Worse](#)

Researchers debated a new approach to tackle TDP43 pathology in ALS at the 5th RNA Metabolism in Neurological Disease Conference held on November 1-2 in San Diego, California.

[Going the Distance: FUS Travels to Terminals, Drops Off RNA](#)

A block in intra-axonal protein synthesis may be a key source of neurotoxicity in FUS ALS according to new results presented at the 5th RNA Metabolism in Neurological Disease Conference. The findings may help explain why some neurons are particularly vulnerable to the disease.

[It's 'And,' Not 'Either-Or': C9ORF72 Mechanisms of Action are Linked](#)

How do repeat expansions in the C9orf72 gene cause ALS and FTD? Experts weighed in at the 5th RNA Metabolism in Neurological Disease Conference.

[11th ICFTD Meeting in Sydney Sorts Out Clinical Subtypes](#)

Missed the International Conference on Frontotemporal Dementias (ICFTD) in Sydney, Australia last month? Check out this meeting wrap-up.

Research News

[Pig Model of ALS Mimics Human Disease](#)

A new disease model may help scientists to develop therapies for ALS. The SOD1G93A transgenic pig is one of a growing number of large animal models that scientists are developing to help bridge the gap between the bench and the clinic.

Check out [An Emerging ALS Test Is Going to the Dogs](#) to learn more about how large animal models can help scientists develop treatments for ALS.

Deals and Partnerships

[Sanofi Sets Its Sights on RIPK1 in ALS](#)

A new partnership sets the stage for testing an emerging neuroprotectant in the ALS clinic. The milestone-based deal, which could reach at estimated \$1.02 billion USD, will include support for the clinical testing of inhibitors of RIPK1 kinase in ALS. The inhibitors are being developed by Denali Therapeutics in San Francisco, California. The enzyme is increasingly implicated in the destruction of motor neurons in the disease.

To find out more about the emerging role of RIPK1 in ALS, check out [For Motor Neurons to Survive, NEK1 May Be on the Line](#).

Check out [our website](#) to read more of the latest research advances in ALS.

Funding Opportunities:

Last chance to apply for [a research grant](#) from the Thierry Latran Foundation to fund your studies in ALS! **Abstracts due by December 6, 2018.**

December 2018

[McKnight Technological Innovations in Neuroscience](#). Letter of Intent due by **December 10, 2018.**

[Edward Scolnick Prize in Neuroscience](#). McGovern Institute for Brain Research. MIT. Nominations due by **December 15, 2018.**

[Neuroscience Prize](#). Gruber Foundation. Nominations due by **December 15, 2018.**

January 2019

[Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes](#). National Center for Advancing Translational Sciences. Application due by January 7, 2019.

[McKnight Scholar Awards in Neuroscience](#). McKnight Endowment Fund for Neuroscience. Application due by January 7, 2019.

[Frank/Fay Seed Grant Program](#). Brain Research Foundation. Letter of Intent due by January 8, 2019.

NEW! [Postdoctoral Fellowships](#). New York Stem Cell Foundation. Application due by January 9, 2019.

[Research Grants](#). Basic Neuroscience. Whitehall Foundation. Letter of Intent due by January 15, 2019.

[Warren Alpert Scholars - Fellowship Award](#). Warren Alpert Foundation. Application due by January 15, 2019.

[Drug Development Grants](#). Preclinical and Phase 1 ALS Clinical Trials. Fight MND. Letter of Intent due by January 19, 2019.

[Clinical Trial Grants](#). Phase 2 and 3 ALS Clinical Trials. Fight MND. Letter of Intent due by January 19, 2019.

February 2019

NEW! [Klingenstein-Simons Fellowship Awards in Neuroscience](#). Application due by February 15, 2019.

NEW! [Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases](#). National Institute of Neurological Disorders and Stroke. Application due by February 18, 2019.

NEW! [Neuroscience Investigator Awards](#). New York Stem Cell Foundation. Application due by February 21, 2019.

NEW! [Stem Cell Investigator Awards](#). New York Stem Cell Foundation. Application due by February 21, 2019.

Check out our [updated list](#) of grants and awards.

Job Opportunities:

[Faculty \(Open Rank\)](#), Neuropathology. University of California. Davis, CA.

[Professor](#), Cell Biology of Neurodegenerative Diseases. Jena University Hospital. Jena, Germany.

[Asst. or Assoc. Professor](#), Neuroscience. Case Western Reserve University. Cleveland, OH.

[Group Leader](#), Neuroscience. Université de Bordeaux. Bordeaux, France.

[Postdoctoral Fellow](#), Bang Lab. Sanford Burnham Prebys Medical Discovery Inst. La Jolla, CA.

[Postdoctoral Fellow](#), Gao Lab. University of Massachusetts Medical School. Worcester, MA.

[Graduate Studentship](#), Kadirkamanathan Lab. University of Sheffield. Sheffield, England.

[Research Assistant](#). University of Oxford. Oxford, England.

[Research Scientist](#). Voyager Therapeutics. Cambridge, MA.

Hiring someone onto your team? Contact us to add your listing to [our updated job board](#): ALSjobs@prize4life.org.

[Full List of Job Opportunities >>](#)

Upcoming Meetings:

Heading to Glasgow? [Download the app](#) for the International Symposia on ALS/MND meeting to access abstracts and the meeting program right on your smart phone!


December 2018

December 6, 2018. Glasgow, Scotland. [ALS/MND Allied Professionals Forum](#).

December 7-9, 2018. Glasgow, Scotland. [International Symposia on ALS/MND](#).


Organizing an ALS meeting? Contact us to add your conference to [our updated calendar](#): ALSmeetings@prize4life.org.

[Full List of Upcoming Meetings>>](#)




[Download the Working with ALS Mice Manual Here](#)

The National
Amyotrophic
Lateral Sclerosis
(ALS) Registry



It's Here!

www.cdc.gov/als
(800) 232-4636



STAY CONNECTED:

